Business
Perimeter Medical Imaging AI Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Perimeter Medical Imaging AI Reports Fourth Quarter and Year-End 2023 Financial Results and Provi...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n \n \n \n Perimeter Medical Imaging AI Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n Conference Call/Webcast Today at\n \n 4:30 pm ET\n \n \n \n \n \n \n \n TORONTO\n \n and\n \n DALLAS\n \n \n ,\n \n \n March 28, 2024\n \n \n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (\"Perimeter\" or the \"Company\") – a commercial-stage medical technology company – today reported financial results for the quarter and year ended\n \n December 31, 2023\n \n and provided a corporate update.\n \n \n \n Adrian Mendes\n \n , Perimeter's Chief Executive Officer stated, \"Reflecting on 2023, I am proud of the considerable progress made since I joined the company mid-year. After conducting a thorough analysis of the business, we focused on four main areas of improvement: strengthening the company's infrastructure to support our planned growth; redeploying clinical education resources to support commercial activities; developing clear roadmaps for our next-gen AI and non-AI products; and accelerating our clinical development plans. In particular, we successfully implemented an enhanced AI algorithm in our ongoing clinical trial evaluating Perimeter's proprietary, investigational B-Series OCT imaging technology combined with \"ImgAssist,\" an AI-driven clinical decision support system created to enhance productivity and decision making in breast cancer surgery margin assessment.\"\n \n \n Mr. Mendes continued, \"As we enter 2024, patient enrollment is outpacing our original projections for our pivotal clinical trial. We continue to execute on our go-to-market strategy to 'seed the market' by adding surgeon champions and reference sites for our S-Series OCT technology, in support of our goal to broaden the user base after our proprietary AI is approved in a breast cancer indication. In addition, our pipeline of product innovations is growing, with several new ...